Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival

Area of Science:

• Oncology
• Health Economics
• Patient-Reported Outcomes

Background:

• Chronic lymphocytic leukemia (CLL) is a largely incurable hematologic malignancy.
• CLL significantly affects patients' health-related quality of life (HRQL).
• Treatment decisions in CLL are often guided by symptom impact on HRQL, leading to potential long-term economic burdens.

Purpose of the Study:

• To quantify the HRQL burden associated with different CLL health states.
• To inform economic evaluations by assigning utility values to CLL health states.

Main Methods:

• Developed nine distinct health states representing CLL treatment lines and disease stages.
• Utilized the time trade-off (TTO) methodology for health state valuation.
• Recruited 100 members of the UK general public to value the defined health states.

Main Results:

• Progression-free survival (PFS) without therapy was valued highest (mean utility = 0.82), indicating the least HRQL burden.
• Relapsed lines of treatment demonstrated the lowest utility values (mean utility = 0.42), signifying the greatest HRQL burden.
• Significant variation in utility values was observed across different CLL health states.

Conclusions:

• Maintaining PFS without therapy is crucial for optimizing HRQL in CLL patients.
• The study provides valuable utility data for economic models assessing the cost-effectiveness of CLL interventions.
• Understanding patient preferences for different health states is essential for comprehensive CLL management.